Pharmazac launches Abelfiz (aripiprazole)

Pharmazac launches Abelfiz (aripiprazole) in 10mg, 15mg and 30mg hard tablets for the treatment of schizophrenia in adults and adolescents aged 15 years and older. Abelfiz is indicated for the treatment of moderate to severe manic episodes in bipolar I disorder and the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. It is also indicated for the treatment of moderate to severe manic episodes in bipolar I disorder in adolescents aged 13 years and older, for up to 12 weeks.